Table 3.
Patient IDa | Underlying disease | CSF JCV DNA log c/mL | JCV VP1 subtypeb | PML-associated substitution | No. of clones with substitution/no. of clones analyzed | |
1 | 5088 | HIV | 3.71 | 4v-164K | none | 0/3 |
2 | 5168 | HIV | 3.39 | 1B | none | PCRc |
3 | 5211 | HIV | 4.43 | 2B | none | PCR |
4 | 5162 (0) | HIV | 4.12 | 2B | 50-51del; D66G; N124S | 22/22; 3/22; 2/22 |
5162 (230) | 4.49 | 2B | 50-51 del | 44/44 | ||
5162 (719-r) | 3.68 | 2B | 50-51del;124-133 del | PCR | ||
5 | 5005 (0) | HIV | 3.49 | 1B | L55F | 9/9 |
5005 (17) | 4.87 | 1B | L55F | 23/23 | ||
5005 (92) | 3.47 | 1B | L55F | 48/48 | ||
6 | 5013 | HIV | 6.55 | 1A | L55F | 21/21 |
7 | 5031 | HIV | 6.12 | 3 | L55F; Q271H | 18/22; 4/22d |
8 | 5087 | HIV | 4.39 | 1B | L55F | 19/19 |
9 | 5092 | HIV | 5.6 | 1A | L55F | 20/20 |
10 | 5108 | HIV | 5.87 | 4-v128A,345K | L55F | 24/24 |
11 | 5135 | HIV | 3.94 | 1A-v75K,308R | L55F | PCR |
12 | 5177 | HIV | 6.51 | 1A | L55F | PCR |
13 | 5053 | HIV | 4.05 | 2B | L55F | PCR |
14 | 5175 | HIV | 4.26 | 2B-v264I,308R | K60M | PCR |
15 | 5169 (0) | HIV | 5.41 | 1B | S61L; 54-55 del | 15/22; 4/22d |
5169 (26) | 4.30 | 1B | S61L | PCR | ||
16 | 5067 | HIV | 4.18 | 1A | H122R | 27/27 |
17 | 5152 (0) | HIV | 3.61 | 1A | H122R; A2V | 44/46; 45/46 |
5152 (487) | 3.80 | 1A | H122R; A2V | 35/36; 35/36 | ||
18 | 5026 | HIV | 3.14 | 1B | 123-125 del | 8/8 |
19 | 5009 (0) | HIV | 2.75 | 4-v128A | N265D | 41/41 |
5009 (225-r) | 2.75 | 4-v128A | N265D | PCR | ||
20 | 5016 (0) | HIV | 6.24 | 4-v128A | N265D | 23/23 |
5016 (56) | 8.59 | 4-v128A | N265D | 48/48 | ||
21 | 5050 | HIV | 5.03 | 4 | Q271R | PCR |
22 | 5007 | HIV | 6.89 | 1B | S267F; S61L; Q271H | 15/22; 4/22; 2/22d |
23 | 5033 | HIV | 4.1 | 2B | S267F | 42/42 |
24 | 5029 | HIV | 6.78 | 2B-v74T,345K | S269F | 21/22 |
25 | 5174 | HIV | 7.62 | 1B | S269F | 28/28 |
26 | 5147 | HIV | 3.95 | 2B | S269F | PCR |
27 | 5040 (0) | HIV | 5.93 | 1A-v75K,128S | S269F | PCR |
5040 (3128-r) | 4.28 | 1A-v75K,128S | None | 0/14 | ||
28 | 5180 | HIV | 4.96 | 1A | S269F | PCR |
29 | 5058 | HIV | 4.53 | 1A-v75K | S269F | PCR |
30 | 5202 | HIV | 6.6 | Undet.e | S269Y | PCR |
31 | 5064 (0) | SLE | 4.31 | 2B | L55F | 47/47 |
5064 (66) | 2.98 | 2B | L55F | 23/23 | ||
32 | 5201 | NHL | 7 | 1B | K60N | PCR |
33 | 5041 | NHL | 5.54 | 2B | N265H | 20/20 |
34 | 5167 | ICL | 3.63 | 2B-v69D, 128A | S267Y | PCR |
35 | 5060 | NHL | 6.24 | 2B | S269F | 23/23 |
36 | 5121 | NHL | 3.62 | 1B-v117T | S269F | 41/41 |
37 | 5138 | NHL | 4.01 | 1B | S269F | 19/19 |
38 | 5166 | NHL | 4.78 | 1A | S269F | 14/14 |
39 | 5207 | NHL, SCT | 6.39 | 1B | Q271H | PCR |
40 | 5097 | Hyper IgE syndrome | 5.69 | 1B | V283I | PCR |
NOTE. JCV indicates JC virus; VP1, viral protein 1; PML, progressive multifocal leukoencephalopathy; HIV, human immunodeficiency virus; PCR, polymerase chain reaction; Undet., undetermined; SLE, systemic lupus erythematosus; NHL, non-Hodgkin lymphoma; ICL, Idiopathic CD4 lymphopenia; SCT, stem cell transplantation.
Number in parentheses indicate the number of days from first sample examined.
According to [8]. The subgroup followed by āvā and position indicates subgroup variant and polymorphism relative to that subtype.
PCR, sequence information was obtained directly from a PCR product without cloning.
Different mutations were observed in different clones.
Sequence available up to position 295.